[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attention-deficit-hyerpactivity-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attention-deficit-hyerpactivity-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100613984","assessing-real-life-effectiveness-of-treatment-in-neurodevelopmental-disorders-100613984",false,"NCT07273695","Assessing Real Life Effectiveness of Treatment in Neurodevelopmental Disorders","ALERT","Inclusion Criteria\n\n* Children and adolescents aged 8-15 years;\n* Diagnosis of externalizing disorder, ADHD, and\u002For emotional dysregulation (assessed with questionnaires, interviews, and\u002For clinical observation);\n* Intelligence quotient ≥ 75.\n\nExclusion Criteria\n\n* IQ \\\u003C 75;\n* Substance abuse and addictions;\n* Psychosis;\n* Acute disorders;\n* Organic brain disorders;\n* Presence of neurological diseases, epilepsy;\n* Genetic syndromes;\n* Co-diagnosis with other psychiatric or neurodevelopmental disorders (e.g., autism, anxiety, depression, etc.) and prior psychopharmacological therapy will not be considered exclusion criteria but will be recorded and declared.","ALL","8 Years","15 Years",{"count":20,"type":21},80,"ESTIMATED","9 Months","OBSERVATIONAL","The goal of this observational study is to learn if and how pharmacological and psychotherapeutic group treatments can treat clinical symptoms of children and adolescent patients with ADHD.\n\nThe main questions it aims to answer are:\n\n* Are pharmacological and psychotherapeutic treatments effective on the clinical symptoms of patients with ADHD?\n* Are pharmacological and psychotherapeutic treatments effective on symptoms of emotion-behavioral dysregulation?\n* Is it possible to find associations between individual characteristics and treatment responses evaluating behavioral and neural correlates in children and adolescents with traits of emotion-behavioral dysregulation, externalizing disorders, and\u002For ADHD, using a panel of multimodal measures. May the data collected contribute to the definition of profiles useful for generating predictive hypotheses aimed at developing more personalized interventions?\n\nResearchers will compare the data collected from patients treated with pharmacological and psychotherapeutic group treatments with the data of subjects of comparable sex\u002Fgender, age, diagnoses, on the waiting list for treatment to see if pharmacological and psychotherapeutic treatments effects ADHD and emotional dysregulation symprtoms.\n\nParticipants, patients who are offered treatment by clinicians according to standard clinical practice, will be asked to participate in the study by undergoing experimental assessments before and after the treatment.\n\nThe multimodal panel of proposed assessments includes:\n\n* behavioral assessments, conducted through the completion of clinical and socio-demographic questionnaires;\n* neuropsychological assessments, conducted through standardized computerized neuropsychological tests;\n* neurophysiological assessments, conducted through the recording of NIRS (near infrared spectroscopy) and EEG (electroencephalogram) signals during an attentional task (Go-NoGo) and via a smartwatch.",[26,27,28,29,30,31],"Emotional Dysregulation","Externalizing Problems","Oppositional Defiant","Conduct Disorder","Disruptive Behaviours","Attention Deficit Hyerpactivity Disorder",[33,34,35,36,37],"attention deficit hyperactivity disorder","child training","methylphenidate","emotional dysregulation","externalizing disorders\u002Fbehaviors","RECRUITING","2025-11-28",{"date":41,"type":42},"2025-12-09","ACTUAL",{"date":44,"type":42},"2025-09-19",{"date":46,"type":21},"2026-12",{"name":48,"class":49},"IRCCS Eugenio Medea","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":50},"100610520","adhd-remote-technology-and-adhd-transition-predicting-and-preventing-negative-outcomes-100610520","NCT07228650","ADHD Remote Technology and ADHD Transition: Predicting and Preventing Negative Outcomes","ART-transition","Inclusion Criteria:\n\n* Diagnosis of DSM-5 ADHD\n* Aged 16-17\n* Able to give informed consent for participation\n* Willing and able to complete self-reported assessments via smartphone\n* Willing to use either their own compatible Android phone or a study Android - phone as their only smartphone during the data collection period\n* Willing to wear the wearable device during the data collection period\n\nExclusion criteria\n\n* Psychosis, currently experiencing a major depressive episode, mania, drug dependence in the last six months, or a major neurological disorder.\n* Recent contact with psychiatric acute care (admission, crisis team or liaison team (A\\&E) in the last six months\n* Any other major medical disease which might impact upon the patient's ability to participate in normal daily activities (e.g., due to hospitalisations)\n* Pregnancy\n* IQ \\\u003C 70\n\nInformant Inclusion Criteria:\n\n* A parent or guardian, as chosen by the participant with ADHD\n* Aged 18 or over\n* Willing and able to complete web-based questionnaires regarding the participant with ADHD","16 Years","17 Years",{"count":61,"type":21},500,"Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental condition affecting 5.9% of young people. Late adolescence can be a particularly challenging period for young people with ADHD, with major life transitions, new demands and increased expectations. This vulnerable phase also coincides with the transition from child and adolescent mental health care to adult ADHD services, where new UK data show that most young people with ADHD do not successfully transfer to adult services. Therefore, many young people with ADHD do not receive appropriate interventions at a time when they may need them most. Opportunities for intervention are currently not fully realised due to both the young people's disengagement from clinical services and our limited understanding of real-world targets for more holistic interventions. The current study seeks to address these needs using remote (not in-person) measurement technology (RMT). The MRC-funded project, ART-transition, will use the ADHD Remote Technology ('ART') assessment and monitoring assessments with young people with a diagnosis of ADHD aged 16-17 and the RADAR-base mobile-health platform to which it is linked. ART consists of active (e.g. questionnaires) and passive (e.g. sleep) smartphone app monitoring. In the study, the investigators will address three questions on the transition to adulthood for individuals with ADHD: what changes take place, what predicts them, and how can the investigators prevent negative outcomes and support healthy lifestyles? The investigators will remotely monitor 250 young people with ADHD over two years. The investigators will then co-design, with young people with ADHD, a prototype for a new ADHD-transition smartphone app. Our approach focuses on giving young people with ADHD greater autonomy in how they manage their ADHD, in collaboration with their clinician, and places the emphasis on modifiable environmental factors and the prevention of negative outcomes.",[31],[65,66,67,68,69,70,71],"ADHD","attention-deficit\u002Fhyperactivity disorder","remote measurement technology","mHealth","Adolescence","medication adherence","Longitudinal","2025-11-20",{"date":74,"type":42},"2025-11-26",{"date":76,"type":42},"2025-02-17",{"date":78,"type":21},"2028-04",{"name":80,"class":49},"King's College London",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":59,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100600076","reducing-smartphone-overuse-for-adolescents-with-attention-deficit-hyperactive-disorder-100600076","NCT07092787","Reducing Smartphone Overuse for Adolescents With Attention-Deficit Hyperactive Disorder","Reducing Smartphone Overuse for Adolescents With Attention-Deficit Hyperactive Disorder: A Randomized Controlled Trial","Inclusion Criteria:\n\n* full-scale IQ above 85\n* right-handedness to control for hemispheric dominance\n* a confirmed diagnosis of ADHD\n* ratings of current symptoms of ADHD on the Strengths and Weaknesses of Attention Deficit Hyperactivity Disorder Symptoms and Normal Behaviour Scale\n* on a stable dose of ADHD medication for at least 4 weeks prior to trial entry or was taking no medication, with no plan to start or change medication type or dosage for the duration of the study\n* over 2 hours of daily smartphone use within the last 4 weeks excluding educational apps\n* a total score on the Smartphone Addiction Scale - Short Version (SAS-SV) above 31 and 33 for male and female adolescents, respectively\n\nExclusion Criteria:\n\n* severe physical or sensory disabilities that may alter the participation in the intervention\n* major depressive episode, bipolar disorder, substance abuse\u002Fdependence within the last 6 months\n* significant neurological conditions (e.g., epilepsy, traumatic brain injury) that could affect cognitive and behavioral functioning\n* concurrent participation in other ADHD interventions (e.g., clinical trials) excluding standard care","12 Years",{"count":90,"type":21},120,"INTERVENTIONAL",[93],"NA","This study will develop and evaluate a smartphone-based behavioral intervention for adolescents with Attention-Deficit Hyperactive Disorder (ADHD) and smartphone overuse in Hong Kong. The main questions it aims to answer are:\n\n* Can a smartphone-based intervention lower self-reported smartphone dependence and objective smartphone usage?\n* Can a smartphone-based intervention lower parent-rated and self-rated ADHD symptoms?\n* Are there differences in electroencephalogram (EEG) in the smartphone salient vs smartphone non-salient conditions after intervention?\n\nAdolescent participants will:\n\n* report weekly smartphone use patterns based on app screencap for 12 weeks\n* complete online surveys on smartphone dependency and ADHD symptoms for 3 times\n* receive 10-minute EEG recordings to gather resting-state EEG data in a natural and relaxing state for 3 times\n\nParent participants will:\n\n* provide a valid clinical report to confirm the adolescent's diagnosis of ADHD\n* complete online surveys to report on the adolescent's smartphone usage and ADHD symptoms for 3 times",[31,96],"Smartphone Addiction","NOT_YET_RECRUITING","2025-07-21",{"date":100,"type":42},"2025-07-30",{"date":102,"type":21},"2025-09",{"date":104,"type":21},"2028-06",{"name":106,"class":49},"Education University of Hong Kong"]